BCNU-associated pneumonitis: portrait of a toxicity
Authors:
Open Access
- 31 January 2012
- journal article
- editorial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (6) , 1019-1020
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplantLeukemia & Lymphoma, 2012
- An Official American Thoracic Society Research Statement: Noninfectious Lung Injury after Hematopoietic Stem Cell Transplantation: Idiopathic Pneumonia SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Pulmonary Drug Toxicity: Radiologic and Pathologic ManifestationsRadioGraphics, 2000
- Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignanciesBone Marrow Transplantation, 2000
- Delayed Pulmonary Toxicity Syndrome following High-dose Chemotherapy and Bone Marrow Transplantation for Breast CancerAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's diseaseBritish Journal of Cancer, 1997
- High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.Journal of Clinical Oncology, 1993
- Autologous bone-marrow transplantation: host effects of high-dose BCNU.Journal of Clinical Oncology, 1983
- Prediction of BCNU Pulmonary Toxicity in Patients with Malignant GliomasNew England Journal of Medicine, 1980